Discovery and History of CTC

What is CTC?

CTC (Circulating Tumor Cells) refers to tumor cells present in the blood of cancer patients. Typically, cancer cells remain localized in a specific area, but some of these cells can enter the bloodstream and spread throughout the body. These circulating cells are known as CTCs and serve as important indicators of cancer metastasis and progression.

Discovery and Early Research of CTC

1. Initial Discovery of CTC

The existence of CTCs was first reported in the 19th century. In 1869, Australian physician Thomas Ashworth was the first to identify tumor cells in the blood of a cancer patient. His discovery laid the groundwork for subsequent CTC research, offering new insights into the mechanisms of cancer metastasis.

2. Early Technical Challenges

Research on CTCs faced numerous technical challenges in its early stages. Since CTCs are extremely rare in blood, they were difficult to detect using traditional microscopy techniques. As a result, CTC research stagnated for some time, but it regained attention with technological advancements in the latter half of the 20th century.

Advancements in CTC Research in the Late 20th Century

1. Introduction of Flow Cytometry

During the 1970s and 1980s, flow cytometry technology was introduced, enabling the rapid and precise analysis of cells in the blood. This breakthrough made the detection of CTCs a reality, marking a significant milestone in CTC research.

2. Development of Monoclonal Antibodies

In the 1980s, the development of monoclonal antibodies advanced, allowing specific labeling and detection of CTCs. Monoclonal antibodies are used to identify particular proteins on the surface of CTCs. This technological advancement further accelerated CTC research.

CTC Research and Clinical Applications in the 21st Century

1. Advances in Microfluidic Technology

The 21st century saw the advent of microfluidic technology, which revolutionized CTC research. This technology enables the rapid and efficient separation of CTCs from blood samples, significantly improving the accuracy of CTC detection. Microfluidic technology has made the clinical application of CTCs a reality.

2. Introduction of Genetic Analysis Techniques

The introduction of next-generation sequencing technology made it possible to perform genetic analysis on CTCs. This advancement has facilitated detailed analysis of the genetic characteristics and mutations of CTCs, promoting the development of personalized medicine, where treatment is tailored to the individual patient. Genetic analysis technology has opened new possibilities in CTC research.

3. Widespread Adoption of Liquid Biopsy

CTC testing has begun to be widely adopted as part of liquid biopsy, a non-invasive method of evaluating cancer status through blood tests. CTC testing plays a central role in liquid biopsy, which is useful for the early detection of cancer and monitoring treatment effectiveness.

Clinical Applications and Significance of CTC

1. Early Detection and Diagnosis

CTC testing holds great potential for the early detection of cancer. By detecting CTCs through blood tests, the presence of cancer can be quickly confirmed, allowing for the early initiation of treatment. This is especially important for high-risk patients and those requiring regular monitoring, making CTC testing a crucial tool.

2. Monitoring Treatment Effectiveness

By monitoring the number and characteristics of CTCs, the effectiveness of treatment can be evaluated. Tracking changes in CTCs before and during treatment allows real-time assessment of treatment efficacy and helps in revising treatment plans. This approach enhances treatment success rates while minimizing side effects.

3. Prediction of Recurrence and Metastasis

CTCs are also useful in predicting cancer recurrence and metastasis. Post-treatment CTC testing can detect early signs of recurrence or metastasis, enabling prompt intervention and improving patient prognosis.

4. Advancement of Personalized Medicine

Analyzing CTCs provides information on the genetic characteristics and drug resistance of cancer cells. This information enables the selection of the most appropriate treatment for each patient, promoting personalized medicine. Personalized medicine aims to provide effective treatment while minimizing side effects.

Challenges and Future Prospects of CTC Testing

1. Improving Detection Accuracy

The biggest challenge in CTC testing is detection accuracy. Due to the extremely low number of CTCs in blood, high-precision detection technology is required. Future research is expected to develop even more accurate detection techniques.

2. Need for Standardization

Standardization of CTC testing is also a significant challenge. Variations in detection and analysis methods can lead to discrepancies in result interpretation. Establishing standardized testing protocols is necessary.

3. Insurance Coverage and Widespread Adoption

Currently, CTC testing is often not covered by insurance, but there is potential for it to be included in the future. If covered by insurance, CTC testing would become more accessible to many patients, generalizing early cancer detection and treatment monitoring.

Conclusion

CTCs (Circulating Tumor Cells) play a crucial role in the early detection of cancer and monitoring treatment effectiveness. From their initial discovery in the 19th century, through technological advancements in the late 20th century, to the introduction of genetic analysis techniques in the 21st century, CTC research has made remarkable progress. CTC testing is becoming widely adopted as part of liquid biopsy and symbolizes the evolution of cancer diagnostic technology.

For individuals concerned about cancer risks, CTC testing holds great promise in early detection, evaluation of treatment effectiveness, and prediction of recurrence and metastasis. With future technological advancements and progress in standardization, it is expected that CTC testing will become even more common and play a significant role in cancer treatment.

CTC Testing at Hiro Clinic

At Hiro Clinic, we offer cutting-edge CTC testing. By detecting Circulating Tumor Cells (CTCs) in the blood, we support the early detection of cancer and the monitoring of treatment effectiveness. This non-invasive blood test is characterized by minimal patient burden. With the latest technology and expertise, we provide reassurance and reliable medical services to those concerned about cancer risks.

Supervisor of the article

---

Dr. Hiroshi Oka

Director of CAP Laboratory

Graduated from Keio University, Faculty of Medicine

Doctor of Medicine

Medical Doctor